ES2127178T3 - Forma amorfa de aztreonam. - Google Patents

Forma amorfa de aztreonam.

Info

Publication number
ES2127178T3
ES2127178T3 ES88110480T ES88110480T ES2127178T3 ES 2127178 T3 ES2127178 T3 ES 2127178T3 ES 88110480 T ES88110480 T ES 88110480T ES 88110480 T ES88110480 T ES 88110480T ES 2127178 T3 ES2127178 T3 ES 2127178T3
Authority
ES
Spain
Prior art keywords
aztreonam
amorphic form
amorphic
methylethoxy
ami
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88110480T
Other languages
English (en)
Inventor
Sailesh Amilal Varia
George Eugene Reier
James Douglas Pipkin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
ER Squibb and Sons LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ER Squibb and Sons LLC filed Critical ER Squibb and Sons LLC
Application granted granted Critical
Publication of ES2127178T3 publication Critical patent/ES2127178T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCION SE REFIERE A LA PREPARACION DE FORMA AMORFA NO-CRISTALINA DEL ACIDO [3S-[3 ALFA (Z), 4 BETA]-3[[2-AMINO-4TIAZOLIL [1-CARBOXI-1-METILETOXI)-IMINO]ACETIL]AMINO]-4METIL-2-OXO-1-AZETIDINOSULFONICO Y DE SUS SALES FARMACEUTICAMENTE.
ES88110480T 1987-07-01 1988-06-30 Forma amorfa de aztreonam. Expired - Lifetime ES2127178T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6839287A 1987-07-01 1987-07-01

Publications (1)

Publication Number Publication Date
ES2127178T3 true ES2127178T3 (es) 1999-04-16

Family

ID=22082279

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88110480T Expired - Lifetime ES2127178T3 (es) 1987-07-01 1988-06-30 Forma amorfa de aztreonam.

Country Status (9)

Country Link
EP (1) EP0297580B1 (es)
JP (1) JP2701869B2 (es)
KR (1) KR890002141A (es)
CN (1) CN1028234C (es)
AT (1) ATE175965T1 (es)
CA (1) CA1339136C (es)
DE (1) DE3856297T2 (es)
ES (1) ES2127178T3 (es)
GR (1) GR3029873T3 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN191492B (es) * 1999-05-25 2003-12-06 Ranbaxy Lab Ltd
DE60137273D1 (de) 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
PT2301524E (pt) 2000-12-27 2013-07-10 Gilead Sciences Inc Aztreonam inalável sem arginina para tratamento e prevenção de infecções bacterianas pulmonares
US7138419B2 (en) 2000-12-27 2006-11-21 Corus Pharma, Inc. Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
US7214364B2 (en) 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
WO2004013133A1 (en) 2002-08-05 2004-02-12 TEVA Gyógyszergyár Részvénytársaság Preparation of aztreonam
WO2004052333A1 (en) * 2002-12-11 2004-06-24 Pari Gmbh Pharmaceutical compositions for the pulmonary delivery of aztreonam
ATE508747T1 (de) 2003-03-10 2011-05-15 Eisai R&D Man Co Ltd C-kit kinase-hemmer
US7452991B2 (en) 2003-05-15 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Aztreonam β polymorph with very low residual solvent content
US7262293B2 (en) 2003-07-02 2007-08-28 Corus Pharma Aztreonam L-lysine and methods for the preparation thereof
PL1698623T3 (pl) 2003-12-25 2015-08-31 Eisai R&D Man Co Ltd Postać krystaliczna soli 4-(3-chloro-4-(cyklopropyloaminokarbonylo)aminofenoksy)-7-metoksy-6-chinolinokarboksamidu lub jej solwatu i sposoby ich wytwarzania
AU2005283422C1 (en) 2004-09-17 2017-02-02 Eisai R & D Management Co., Ltd. Medicinal composition
ATE423115T1 (de) 2005-05-09 2009-03-15 Sicor Inc Herstellungsverfahren für aztreonam
US7550483B2 (en) 2005-06-23 2009-06-23 Eisai R&D Management Co., Ltd. Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same
JP4733700B2 (ja) * 2005-06-23 2011-07-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 ４−（３−クロロ−４−（シクロプロピルアミノカルボニル）アミノフェノキシ）−７−メトキシ−６−キノリンカルボキサミドの塩のアモルファスおよびその製造方法
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
RU2448708C3 (ru) 2006-05-18 2017-09-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство против рака щитовидной железы
CN101511793B (zh) 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
CN101600694A (zh) 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
KR101513326B1 (ko) 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
CN101579336B (zh) * 2009-07-07 2010-06-23 重庆市庆余堂制药有限公司 一种注射用氨曲南及其生产方法
DK2468281T3 (en) 2009-08-19 2016-03-21 Eisai R&D Man Co Ltd Quinolinderivatholdig pharmaceutical composition
WO2011162343A1 (ja) 2010-06-25 2011-12-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤
CN101912356B (zh) * 2010-08-02 2012-01-11 王明 一种氨曲南/精氨酸药物组合物脂微球注射剂
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
EP2997377B1 (en) 2013-05-14 2018-07-18 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
AU2016224583B2 (en) 2015-02-25 2021-06-03 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
EP3624800A4 (en) 2017-05-16 2021-02-17 Eisai R&D Management Co., Ltd. TREATMENT OF HEPATOCELLULAR CARCINOMA

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1181075A (en) * 1981-07-13 1985-01-15 David M. Floyd CRYSTALLINE ANHYDROUS FORM OF [3-S-[3.alpha.(Z),4 .beta.]]-3-[[(2-AMINO-4-THIAZOLYL) [(1-CARBOXY-1-METHYLETHOXY)IMINO]ACETYL] AMINO]-4-METHYL-2-OXO-1-AZETIDINESULFONIC ACID
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile

Also Published As

Publication number Publication date
GR3029873T3 (en) 1999-07-30
EP0297580A1 (en) 1989-01-04
CA1339136C (en) 1997-07-29
DE3856297T2 (de) 1999-06-02
EP0297580B1 (en) 1999-01-20
KR890002141A (ko) 1989-04-08
CN1028234C (zh) 1995-04-19
JP2701869B2 (ja) 1998-01-21
CN1030238A (zh) 1989-01-11
DE3856297D1 (de) 1999-03-04
JPS6422874A (en) 1989-01-25
ATE175965T1 (de) 1999-02-15

Similar Documents

Publication Publication Date Title
ES2127178T3 (es) Forma amorfa de aztreonam.
CA2418125A1 (en) Beta-lactams useful in the preparation of substituted isoserine esters
CA2333938A1 (en) New 3-aryl-2-hydroxypropionic acid derivative (i)
AU557096B2 (en) Thiazole derivatives
ATE123778T1 (de) Beta-lactam-derivate.
YU117185A (en) Process for obtaining 2-substituted-1,3 propyl of idenediphosphonate derivatives
DE69017174D1 (de) Substituierte Oxophtalazinyl-Essigsäuren und deren Analogen.
NO912992L (no) 1-aminopropandiol-2,3 med hoey renhet, samt fremgangsmaate for fremstilling av forbindelsen.
FI864970A0 (fi) Nya kristallina salter av aryloxi-propanolaminer, foerfarande foer deras framstaellning och deras anvaendning.
EP0342423A3 (en) Heteroaroylhydrazide derivatives of monocyclic beta-lactam antibiotics
AU584270B2 (en) Novel derivatives of erythromycylamine
DE69012145D1 (de) Beta-lactamderivate.
MY108199A (en) Tricyclic pyridone derivative
FI891866A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten sulfonanilidien valmistamiseksi
SE8705068L (sv) Kristallina salter av /3s(z)/-2-///1-(2-amino-4-tiazolyl)-2-//2,2-dimetyl-4-oxo-1-(sulfooxi)-3-azetidinyl/-amino/-2-oxoetyliden/-amino/oxi/ettiksyra
EP0413278A3 (en) Use of xanthine derivatives against peptic ulcers
IT1190660B (it) Composto ad attivita' mucoregolatrice e antitosse,procedimento per la sua preparazione e relative composizioni farmaceutiche
CA2011668A1 (en) Germicidal composition
IT1190661B (it) Composto ad attivita' mucoregolatrice e fluidificante,procedimento per la sua preparazione e relative composizioni farmaceutiche
FI893001A7 (fi) Menetelmä uusien, terapeuttisesti käyttökelpoisten 1,2-bentsisoksatsol-3-yyli- ja 1,2-bentsisotiatsol-3-yylijohdannaisten valmistamiseksi
CA1271749C (en) HYDRAZIDE DERIVATIVES OF MONOCYCLIC .BETA.-LACTAMS WITH ANTIBIOTIC PROPERTIES
JPS57129455A (en) Stylus cleaning mechanism
ES2009936A6 (es) Procedimiento para obtener ciprofloxacina.
IT8920126A0 (it) Derivato di 4 (piperidin 1 il)pipiridina ad attivita' antifibroplastica.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 297580

Country of ref document: ES